| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
96,118,000 |
| Market
Cap: |
1.54(B) |
| Last
Volume: |
115,349 |
Avg
Vol: |
114,420 |
| 52
Week Range: |
$15.99 - $15.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avadel Pharmaceuticals is a biopharmaceutical company. Co.'s primary product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients. Co.'s commercial products are: Akovaz, which is indicated for the treatment of hypotension occurring in the setting of anesthesia; Bloxiverz, which is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep®, which is for the treatment of hypotension occuring in the setting of anesthesia; and Nouress, which is a sterile injectable product for use in the hospital setting.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
45,000 |
85,579 |
113,579 |
| Total Buy Value |
$0 |
$355,308 |
$761,676 |
$1,139,173 |
| Total People Bought |
0 |
3 |
6 |
6 |
| Total Buy Transactions |
0 |
3 |
9 |
13 |
| Total Shares Sold |
0 |
0 |
0 |
103,975 |
| Total Sell Value |
$0 |
$0 |
$0 |
$1,522,364 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mchugh Thomas S |
Chief Financial Officer |
• – – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
12,600 |
100,400 |
|
- |
|
| Divis Greg J |
Chief Executive Officer |
• • – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
52,000 |
211,100 |
|
- |
|
| Seurer Jerad G. |
Gen. Counsel & Corp. Secretary |
• – – |
2025-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
14,700 |
23,495 |
|
- |
|
| Palczuk Linda |
Director |
– • – |
2025-01-21 |
4 |
B |
$7.93 |
$39,640 |
D/D |
5,000 |
67,900 |
2.39 |
- |
|
| Thornton Peter |
Director |
– • – |
2025-01-13 |
4 |
B |
$8.05 |
$80,450 |
D/D |
10,000 |
104,055 |
2.39 |
- |
|
| Ende Eric J |
Director |
– • – |
2025-01-13 |
4 |
B |
$7.84 |
$235,218 |
D/D |
30,000 |
208,900 |
2.39 |
- |
|
| Palczuk Linda |
Director |
– • – |
2024-12-24 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,500 |
62,900 |
|
- |
|
| Mchugh Thomas S |
Chief Financial Officer |
• – – |
2024-12-13 |
4 |
B |
$10.44 |
$24,019 |
D/D |
2,300 |
87,800 |
2.74 |
- |
|
| Mchugh Thomas S |
Chief Financial Officer |
• – – |
2024-12-11 |
4 |
B |
$10.49 |
$52,433 |
D/D |
5,000 |
85,500 |
2.74 |
- |
|
| Glass Geoffrey Michael |
Director |
– • – |
2024-12-10 |
4 |
B |
$9.80 |
$199,641 |
I/I |
20,279 |
75,904 |
2.1 |
- |
|
| Divis Greg J |
Chief Executive Officer |
• • – |
2024-12-09 |
4 |
B |
$9.82 |
$3,948 |
I/I |
402 |
10,000 |
2.58 |
- |
|
| Divis Greg J |
Chief Executive Officer |
• • – |
2024-12-06 |
4 |
B |
$9.98 |
$95,759 |
I/I |
9,598 |
9,598 |
2.66 |
- |
|
| Palczuk Linda |
Director |
– • – |
2024-12-06 |
4 |
B |
$10.19 |
$30,568 |
D/D |
3,000 |
66,400 |
2.39 |
- |
|
| Palczuk Linda |
Director |
– • – |
2024-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
63,400 |
|
- |
|
| Thornton Peter |
Director |
– • – |
2024-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
94,055 |
|
- |
|
| Glass Geoffrey Michael |
Director |
– • – |
2024-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
11,000 |
|
- |
|
| Amin Naseem |
Director |
– • – |
2024-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
11,000 |
|
- |
|
| Ende Eric J |
Director |
– • – |
2024-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
178,900 |
|
- |
|
| Mccamish Mark Anthony |
Director |
– • – |
2024-07-30 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
11,000 |
|
- |
|
| Seurer Jerad G. |
Gen. Counsel & Corp. Secretary |
• – – |
2024-04-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,795 |
|
-100% |
|
| Mchugh Thomas S |
Chief Financial Officer |
• – – |
2024-01-16 |
4 |
B |
$14.50 |
$29,000 |
D/D |
2,000 |
80,500 |
2.74 |
7% |
|
| Mccamish Mark Anthony |
Director |
– • – |
2023-12-28 |
4 |
AS |
$14.53 |
$1,089,750 |
I/I |
(75,000) |
67,025 |
|
10% |
|
| Mchugh Thomas S |
Chief Financial Officer |
• – – |
2023-08-14 |
4 |
B |
$14.45 |
$28,900 |
D/D |
2,000 |
78,500 |
2.74 |
-3% |
|
| Mccamish Mark Anthony |
Director |
– • – |
2023-08-11 |
4 |
S |
$14.93 |
$432,614 |
I/I |
(28,975) |
142,025 |
|
2% |
|
| Divis Greg J |
Chief Executive Officer |
• • – |
2023-08-10 |
4 |
B |
$13.20 |
$131,997 |
D/D |
10,000 |
159,100 |
2.81 |
3% |
|
205 Records found
|
|
Page 1 of 9 |
|
|
